Compare MSD & IPHA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | MSD | IPHA |
|---|---|---|
| Founded | 1993 | 1999 |
| Country | United States | France |
| Employees | N/A | N/A |
| Industry | Trusts Except Educational Religious and Charitable | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 146.9M | 165.3M |
| IPO Year | N/A | 2014 |
| Metric | MSD | IPHA |
|---|---|---|
| Price | $7.26 | $2.15 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 4 |
| Target Price | N/A | ★ $5.75 |
| AVG Volume (30 Days) | 42.2K | ★ 174.9K |
| Earning Date | 01-01-0001 | 03-26-2026 |
| Dividend Yield | ★ 11.26% | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | $180.36 |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $6.91 | $1.18 |
| 52 Week High | $7.94 | $2.71 |
| Indicator | MSD | IPHA |
|---|---|---|
| Relative Strength Index (RSI) | 50.62 | 52.48 |
| Support Level | $7.23 | $1.67 |
| Resistance Level | $7.44 | $2.66 |
| Average True Range (ATR) | 0.06 | 0.08 |
| MACD | 0.00 | -0.02 |
| Stochastic Oscillator | 27.79 | 38.46 |
Morgan Stanley Emerg Mkts Debt Fd Inc is a diversified, closed-end management investment company. The Fund's primary investment objective is to produce high current income and as a secondary objective to seek capital appreciation, through investments mainly in debt securities of government and government-related issuers located in emerging countries, of entities organized to restructure the outstanding debt of such issuers and debt securities of corporate issuers in or organized under the laws of emerging countries.
Innate Pharma SA is a clinical-stage biotechnology company. It is engaged in developing immunotherapies for cancer patients. The company's approach includes therapeutic modalities such as monoclonal antibodies, multispecific NK cell engagers through its ANKET platform, and antibody-drug conjugates (ADC). Its portfolio includes lacutamab, which is being studied for cutaneous T-cell lymphomas and peripheral T-cell lymphomas, and monalizumab, which is being developed in collaboration with AstraZeneca for non-small cell lung cancer. The company's revenue mainly consists of revenues from collaboration and licensing agreements and government financing for research expenditure in the form of research tax credits, as well as other grants.